Drugs / Bivalent Subtype C gp120
last change Mar 2024 re-read 2 minutes ago

Bivalent Subtype C gp120

Vaccine

Developed for
HIV infectious disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03284710 Comparator Jun 2017 → Dec 2019 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Bivalent Subtype C gp120 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03284710
Modality Vaccine “a bivalent gp120 protein vaccine boost” PMID 38502656 Mar 2024